The company's patented platform combines genetics and other factors to predict adverse drug reactions (ADRs) and provide personalized drug reaction risk information to doctors. Cipherome's Xentinel™ platform is designed to reduce the economic, emotional, and societal burden of ADRs by accurately predicting them. The company's team has extensive experience in bioinformatics, advanced genomic sequence analysis algorithms, drug development, and clinical expertise. Anyone, regardless of age, race, or gender, can benefit from Cipherome's genome information. Visit www.cipherome.com to learn more.